BioCentury | Apr 25, 2016
Politics, Policy & Law

SCOTUS to the rescue?

.../ Citius [1] Juxtapid lomitapide from Aegerion [2] Eliquis apixaban from Bristol-Myers / Pfizer [1] Treximet...
BioCentury | Jun 29, 2015
Company News

Tribute Pharmaceuticals, Pozen deal

...Pozen revenues of $32.4 million for the same period. Two of Pozen’s products -- Treximet sumatriptan/naproxen...
BioCentury | May 25, 2015
Clinical News

Treximet sumatriptan/naproxen regulatory update

...FDA approved an sNDA from Pernix for Treximet sumatriptan/naproxen to treat migraine with or without aura...
...triptan with an NSAID and GlaxoSmithKline’s RT dispersion enhancement technology. Pernix has U.S. rights to Treximet...
...N.J. Pozen Inc. (NASDAQ:POZN), Chapel Hill, N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Treximet sumatriptan/naproxen...
BioCentury | Apr 6, 2015
Finance

Q is for quiet

...and ocular hypertension patients Submit NDA 2Q15 Pernix Therapeutics Holdings Inc. (NASDAQ:PTX)/Pozen Inc. (NASDAQ:POZN) Treximet sumatriptan/naproxen...
BioCentury | Feb 16, 2015
Clinical News

Treximet sumatriptan/naproxen regulatory update

...Pernix said FDA accepted for review an sNDA for Treximet sumatriptan/naproxen to treat migraine with or...
...triptan with an NSAID and GlaxoSmithKline’s RT dispersion enhancement technology. Pernix has U.S. rights to Treximet...
...Inc. (NASDAQ:POZN), Chapel Hill, N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Treximet sumatriptan/naproxen (formerly Trexima...
BioCentury | Nov 24, 2014
Clinical News

Treximet sumatriptan/naproxen regulatory update

...Pernix submitted an sNDA to FDA for Treximet sumatriptan/naproxen to treat migraine with or without aura...
...triptan with a NSAID and GlaxoSmithKline’s RT dispersion enhancement technology. Pernix has U.S. rights to Treximet...
...Inc. (NASDAQ:POZN), Chapel Hill, N.C. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Treximet sumatriptan/naproxen (formerly Trexima...
BioCentury | Sep 1, 2014
Company News

GlaxoSmithKline, Pernix Therapeutics deal

...Pernix said the closing of a deal granting GlaxoSmithKline U.S. rights to Treximet sumatriptan/naproxen was delayed...
...inventory situation.” GSK said it identified a cosmetic issue with the “fast-dissolving coating process” for Treximet...
...By year end, Pernix plans to submit a request to FDA for pediatric exclusivity for Treximet...
BioCentury | May 19, 2014
Finance

Highlights of weekly biotech stock moves

...paying GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) $250 million up front to acquire U.S. rights to Treximet sumatriptan/naproxen...
BioCentury | May 19, 2014
Company News

Pernix Therapeutics, Pozen, GlaxoSmithKline, CPP Investment Board deal

...Pernix acquired from GlaxoSmithKline the U.S. rights to Treximet sumatriptan/naproxen to treat migraines for an upfront...
...CPP's CPPIB Credit Investments Inc. unit, which bought royalty and milestone rights associated with U.S. Treximet...
...commercialize additional dosage forms of sumatriptan/naproxen combinations outside the U.S., including the sumatriptan strength in Treximet...
BioCentury | May 19, 2014
Analyst Picks & Changes

Analyst picks & changes

...U.S. rights to migraine drug Treximet sumatriptan/naproxen for $250M up front (see B7). Pernix said Treximet...
Items per page:
1 - 10 of 106